Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Effectiveness of the proposed method to decrease chloroplast contamination. by Gabriela Madrid (11871401)

miRNA 221 improved left ventricular contractile function in MIRI mice. by Hongyu Li (1332669)

Subjects:

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i> by Rayane Brinck Teixeira (6676529)

Fig 17 - by Zhezhe Zhang (19704587)

Subjects:

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. by Hakim Ben Abdallah (14578241)

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. by Francesca Catto (21253435)

“…<p>(A) Each 3-dimensional map of statistically affected voxels (p < 0.05, with the red scale, representing the significance in decrease of microglia, and the cyan scale, representing the increase in microglia; reference atlas is grey) summarizes all the treated and control samples within a cohort (3 samples per group). …”

Thymus regeneration promotes naïve T-cell recovery in iMycTg aging-E mice and a partial decrease in Treg frequencies. by Abigail Morales-Sánchez (21799582)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Significant associations in GWAS. by Dai Nogimura (21445649)

Subjects:

DALY and HLY in Portugal, 1990–2019. The first graph shows a decreasing trend of DALY and the second graph shows an increasing trend of HLY. by Aida Isabel Tavares (12080156)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)